FDA approves GSK’s Hibsago for chronic hepatitis B

Bitget2026/10/20 20:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA approved GSK’s Hibsago (bepirovirsen) for chronic hepatitis B in eligible adults without cirrhosis.
The six-month treatment is used with nucleos(t)ide analogue therapy, with self-administration available following the first dose.
Phase III trials showed a 19% functional cure rate versus 0% with placebo in patients with HBsAg levels ≤3,000 IU/ml.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA approves GSK’s Hibsago for chronic hepatitis B

You may also like

Crypto prices